focus -WSS

focus

author：knowledge 2025-09-06 06:16:33 - browse：26

A sign of Elevance Health behind some flowers — coverage from STAT — Michael Conroy/AP

These days, the surefire way to get ahead in health insurance is to become a health care provider, and Elevance just upped the ante. It’s joining with private equity to launch a $4 billion primary care company.

Elevance leaders divulged more about the company’s venture with Clayton, Dubilier & Rice on its first quarter earnings call Thursday. The partners announced the new company, yet unnamed, earlier this week, but the release was light on detail. The strategic partnership will house Elevance and CD&R’s doctors, clinics, and the technologies that help those doctors manage their patients.

Health insurers specialize in managing medical costs, and through ventures like this, they apply that expertise to managing patients’ chronic medical conditions. In arrangements like Medicare Advantage, where insurers are paid set amounts for members’ care, they’re incentivized to keep those patients healthy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Shionogi licenses Pompe disease therapy from Maze Therapeutics

WSS

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

This gene therapy has record $4.25 million price. It's saved children.

Brain worms: The science behind RFK Jr.'s parasitic infection

Testing GLP

Readout LOUD podcast, live from the STAT Breakthrough Summit East

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Wikipedia

Drug repurposing or repositioning? The language matters

Erich Jarvis studies song birds to learn about human stuttering

Heart attack and stroke risk calculators need revising

First recipient of genetically engineered pig kidney has died

How to save PrEP access — and even expand it

Pfizer, Moderna say biotech, pharma drug development is a sprint

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Biotech investment managers search for lucrative opportunities

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Asbestos ban is immediate, but health effects will linger for decades

Wikipedia

Biotech investment managers search for lucrative opportunities

Readout Newsletter: Sanofi, Novavax, Maze x Shionogi news

Bring on the sabbaticals for nurses

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

What Kate Middleton's cancer revelation might teach the world

knowledge

leisure time

entertainment

leisure time